Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease | Zendy

David Devos | Zendy; Caroline Moreau | Zendy; Jean Christophe Devedjian | Zendy; Jérôme Kluza | Zendy; Maud Pétrault | Zendy; Charlotte Laloux | Zendy; Aurélie Jonneaux | Zendy; Gilles Ryckewaert | Zendy; Guillaume Garçon | Zendy; Nathalie Rouaix | Zendy; Alain Duhamel | Zendy; P. Jissendi | Zendy; Kathy Dujardin | Zendy; F. Auger | Zendy; Laura Ravasi | Zendy; Lucie Hopes | Zendy; Guillaume Grolez | Zendy; Wance Firdaus | Zendy; Bernard Sablonnière | Zendy; Isabelle Strubi-Vuillaume | Zendy; Noël Zahr | Zendy; A. Destée | Zendy; JeanChristophe Corvol | Zendy; Dominik Pöltl | Zendy; Marcel Leist | Zendy; Christian Rosé | Zendy; Luc Defebvre | Zendy; Philippe Marchetti | Zendy; Z. Ioav Cabantchik | Zendy; Régis Bordet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

Author(s) -

David Devos,

Caroline Moreau,

Jean Christophe Devedjian,

Jérôme Kluza,

Maud Pétrault,

Charlotte Laloux,

Aurélie Jonneaux,

Gilles Ryckewaert,

Guillaume Garçon,

Nathalie Rouaix,

Alain Duhamel,

P. Jissendi,

Kathy Dujardin,

F. Auger,

Laura Ravasi,

Lucie Hopes,

Guillaume Grolez,

Wance Firdaus,

Bernard Sablonnière,

Isabelle Strubi-Vuillaume,

Noël Zahr,

A. Destée,

JeanChristophe Corvol,

Dominik Pöltl,

Marcel Leist,

Christian Rosé,

Luc Defebvre,

Philippe Marchetti,

Z. Ioav Cabantchik,

Régis Bordet

Publication year - 2013

Publication title -

antioxidants and redox signaling

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.277

H-Index - 190

eISSN - 1557-7716

pISSN - 1523-0864

DOI - 10.1089/ars.2013.5593

Subject(s) - deferiprone , substantia nigra , oxidative stress , dopamine , parkinson's disease , striatum , deferasirox , medicine , placebo , deferoxamine , clinical trial , disease , pathology , gastroenterology , pharmacology , alternative medicine , thalassemia

The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research